相关实验视频

Updated: Jun 16, 2025

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

由带血液衍生的细胞可以在无形成性贫血动物模型中重建血液形成

Zesong Chen^1,2, Chen Yang¹, Jiang Ji¹

¹Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.

Stem cells international

|August 20, 2024

概括

将带衍生细胞与环素A (CsA) 结合起来,显著改善了小鼠的无形成性贫血 (AA). 带介质干细胞 (UC-MSC) 在恢复血液细胞的产生和免疫功能方面比调节性T细胞 (UCB-Treg) 有更大的有效性.

科学领域:

干细胞疗法干细胞疗法
血液学血液学血液学
免疫学免疫学免疫学

背景情况:

无质性贫血 (AA) 是一种罕见但严重的疾病,其特点是骨髓衰竭.
目前的治疗方法,包括用环素A (CsA) 进行免疫抑制疗法,都有局限性.
带衍生细胞由于其再生和免疫调节性质,提供了潜在的治疗益处.

研究的目的:

为了评估结合带衍生细胞与CsA在非塑性贫血的小鼠模型的疗效.
研究这些细胞疗法改善血液形成和免疫功能的潜在机制.

主要方法:

免疫介导的AA模型小鼠接受了CSA治疗,并与UC介导干细胞 (UC-MSC) 或UC血液调节T细胞 (UCB-Treg) 结合.
对照组接受了UC-MSC,UCB-Treg,单独使用CSA或不接受治疗.
分析了血液学参数,骨髓细胞种群,T细胞子集,血清细胞因子和基因表达 (转录组测序).

主要成果:

与单独的CsA相比,组合疗法 (CsA + UC-MSC或CsA + UCB-Treg) 显著改善了存活率和恢复的白细胞 (WBC),爆发形成单元 (BFU) 和殖民地形成单元-颗粒细胞,巨细胞 (CFU-GM) 数量.
UC-MSC在提高BFU数量和骨髓CD34+细胞比例方面表现出卓越的疗效.
在组合治疗组中,炎症性细胞因子水平 (TNF-α,IL-2,INF-γ) 降低,在UC-MSC (基因组甲基化) 和UCB-Treg (能量代谢) 中观察到明显的分子途径改变.

结论:

将UC-MSC或UCB-Treg添加到CsA显著提高了AA小鼠的造血复苏.
在恢复血液形成和改善免疫异常方面,UC-MSC表现出比UCB-Treg更高的效率.
这些发现突显了带衍生细胞作为无形性贫血的辅助疗法的潜力.

更多相关视频

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

相关概念视频

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...